StockNews.AI
NYXH
StockNews.AI
2 days

Nyxoah Announces Upcoming Investor Events

1. Nyxoah announces participation in upcoming healthcare conferences in September 2025. 2. The Genio system treats Obstructive Sleep Apnea, now FDA approved. 3. Nyxoah's market entry strategy includes direct engagement with institutional investors. 4. CE marked since 2019, showing regulatory compliance with European standards. 5. Positive study outcomes signal potential for market growth in OSA treatment.

7m saved
Insight
Article

FAQ

Why Bullish?

Nyxoah's upcoming investor events signal confidence and potential interest, aligning with historical trends where active engagement often precedes positive stock movement. Significant FDA approval adds credibility to their innovative solutions, enhancing investor sentiment.

How important is it?

The article addresses significant advancements and events for Nyxoah, which could attract investor interest and impact stock performance shortly.

Why Short Term?

The investor conferences are imminent and likely to impact sentiment and share price quickly. Historical precedence shows that announcements and participations in investor events often lead to short-term stock price uplifts.

Related Companies

MDGLNVOSGOEV
Nyxoah Announces Upcoming Investor Events Mont-Saint-Guibert, Belgium – September 2, 2025, 10:30pm CET / 4:30PM ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the following events during September: 2025 Wells Fargo Healthcare ConferenceSeptember 3rd – Boston, MA Cantor Global Healthcare Conference 2025 September 4th – New York, NYFireside Chat: 11:30-12:00 pm ETWebcast: Cantor Fireside Chat Webcast Morgan Stanley 23rd Annual Global Healthcare Conference September 9th – New York, NY Presentation Time: 5:35-6:10 pm ETWebcast: : Morgan Stanley Fireside Chat Webcast Baird's 2025 Global Healthcare Conference September 10th – New York, NY A live webcast of the events can be accessed by visiting Nyxoah’s Investor Relations website and will be available for replay following the events. The Company will also be available for 1x1 meetings with institutional investors attending the events. About NyxoahNyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and U.S. FDA approval of a Premarket Approval application. For more information, please visit http://www.nyxoah.com/. Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device. FORWARD-LOOKING STATEMENTS Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio system; planned and ongoing clinical studies of the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Contacts: NyxoahJohn Landry, CFOIR@nyxoah.com For MediaIn United StatesFINN Partners – Alyssa Paldoalyssa.paldo@finnpartners.com In International/GermanyMC Services – Anne Henneckeanne.hennecke@mc-services.eu In Belgium/FranceBackstage Communication – Gunther De Backergunther@backstagecom.be ENGLISH_Nyxoah Announces Upcoming Investor Events_FINAL

Related News